Kineta Chronic Pain inks $360M+ deal with pharmaceutical giant: 3 things to know

Spinal Tech

Kineta Chronic Pain signed an agreement with pharmaceutical leader Genentech to develop a non-opioid chronic pain treatment, according to CNBC.

Here are three things to know.

1. The upfront payments were not disclosed, however, Kineta is eligible to receive up to $359 million on top of royalty payments.

2. Genentech has the ability to license technologies developed from the collaborations.

3. Early tests of the drug are displaying disease-modifying effects, such as reduced information and nerve protection.

4. Roche purchased Genentech for $46.8 billion in 2009.

5. Kineta was founded in 2008 to develop drugs for chronic pain, autoimmune and infectious diseases.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers